This research indicates that Doxorubicin (Dox)-resistant TNBC cells exhibit increased glycolysis and ATP generation compared ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the most active stocks to buy according to analysts. On June 13, Ethris announced a collaboration with Thermo Fisher Scientific. The partnership aims ...

Researchers develop a self-regulating mRNA medicine that adjusts protein production based on disease-related signals.

Yet, the remaining challenge toward optimizing PM-based mRNA delivery systems for systemic application is to build a functionality to prevent RNase invasion into the polyplex core storing cargo mRNA.

VIDEO: S&P 500 Movers: MRNA, PLTR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Safety data from more than 298 million doses of mRNA COVID-19 vaccine administered in the first 6 months of the US vaccination programme show that most reported adverse events were mild and short in ...

Fact check: HHS misleads on mRNA vaccine safety after pulling Moderna funding The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by ...

HHS Secretary Kennedy, after firing every member of key CDC vaccine advisory panel, appoints eight new members, including critics of mRNA technology.

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ...

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.